Glenn J. Jaffe, MD
Chief, Vitreoretinal Diseases and Surgery Service
Department / Division
Ophthalmology /
Retinal Ophthalmology
Address
DUMC 3802
Durham, NC 27710
Appointment Telephone
919-681-3937
Office Telephone
919-684-6611
Fax Telephone
919-681-6474
- MD, University of California, San Francisco, School of Medicine, 1987
- Vitreoretinal Disease, Medical College of Wisconsin, 1987-1989
Clinical Interests
Vitreoretinal diseases and retinal cell biology, macular holes, retinal detachment, subretinal neovascularization, proliferative diabetic
retinopathy, posterior segment surgical procedures for diagnosis or therapy of uveitis
Research Interests
I have an active basic and clinical research program. I have been principal investigator on several funded clinical studies including investigations of an oral ganciclovir prodrug to treat CMV retinitis and a study to determine the safety of a cyclosporine sustained drug delivery implant in the treatment of uveitis. I am principal investigator of an ongoing multicenter trial of a fluocinolone sustained drug delivery implant to treat patients with severe uveitis and a trial of this same implant to treat diabetic macular edema. Recently, I have investigated the use of ultrasonography and optical coherence tomography to diagnose macular edema in a variety of ocular diseases. I have maintained an ongoing basic research program to test the hypothesis that cytokines are important in the development of proliferative vitreoretinopathy, an important intraocular wound healing disorder. Education: I am actively involved in resident and fellow education. I give lectures to residents and fellows on a variety of topics related to uveitis and vitreoretinal diseases and train fellows to perform vitreoretinal surgery. I train post-doctoral students and medical students to conduct clinically relevant research. I serve as a mentor for the Duke third year medical school research program. I have served on a yearly basis as course faculty at many national and international meetings.
This physician (or a member of their immediate family) has a working relationship (i.e. consulting, research, and/or educational services) with the companies listed below. These relations have been reported to the health system leadership and, when appropriate, management plans are in place to address potential conflicts.
- Abbott Laboratories
- Johnson & Johnson
- Neurotech
- SurModics, Inc.
- pSivida
Representative Publications
Jaffe GJ, Brownlow R, Hines J. Modified external needle drainage procedure for rhegmatogenous retinal detachment. Retina. 2003 Feb;23(1):80-5.
(2003)
Abstract
Lai JC, Stinnett SS, Jaffe GJ. B-scan ultrasonography for the detection of macular thickening. Am J Ophthalmol. 2003 Jul;136(1):55-61.
(2003)
Abstract
Stamer WD, Bok D, Hu J, Jaffe GJ, McKay BS. Aquaporin-1 channels in human retinal pigment epithelium: role in transepithelial water movement. Invest Ophthalmol Vis Sci. 2003 Jun;44(6):2803-8.
(2003)
Abstract
Yang P, McKay BS, Allen JB, Roberts WL, Jaffe GJ. Effect of mutant IkappaB on cytokine-induced activation of NF-kappaB in cultured human RPE cells. Invest Ophthalmol Vis Sci. 2003 Mar;44(3):1339-47.
(2003)
Abstract
Meyer CH, Hotta K, Peterson WM, Toth CA, Jaffe GJ. Effect of INS37217, a P2Y(2) receptor agonist, on experimental retinal detachment and electroretinogram in adult rabbits. Invest Ophthalmol Vis Sci. 2002 Nov;43(11):3567-74.
(2002)
Abstract
Mruthyunjaya P, Jumper JM, McCallum R, Patel DJ, Cox TA, Jaffe GJ. Diagnostic yield of vitrectomy in eyes with suspected posterior segment infection or malignancy. Ophthalmology. 2002 Jun;109(6):1123-9.
(2002)
Abstract
Jaffe GJ, Ben-Nun J, Guo H, Dunn JP, Ashton P. Fluocinolone acetonide sustained drug delivery device to treat severe uveitis. Ophthalmology. 2000 Nov;107(11):2024-33.
(2000)
Abstract
Jaffe GJ, Yang CH, Guo H, Denny JP, Lima C, Ashton P. Safety and pharmacokinetics of an intraocular fluocinolone acetonide sustained delivery device. Invest Ophthalmol Vis Sci. 2000 Oct;41(11):3569-75.
(2000)
Abstract
Jaffe GJ, Yang CS, Wang XC, Cousins SW, Gallemore RP, Ashton P. Intravitreal sustained-release cyclosporine in the treatment of experimental uveitis. Ophthalmology. 1998 Jan;105(1):46-56.
(1998)
Abstract
Yang CS, Khawly JA, Hainsworth DP, Chen SN, Ashton P, Guo H, Jaffe GJ. An intravitreal sustained-release triamcinolone and 5-fluorouracil codrug in the treatment of experimental proliferative vitreoretinopathy. Arch Ophthalmol. 1998 Jan;116(1):69-77.
(1998)
Abstract
Liu NP, Roberts WL, Hale LP, Levesque MC, Patel DD, Lu CL, Jaffe GJ. Expression of CD44 and variant isoforms in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1997 Sep;38(10):2027-37.
(1997)
Abstract
Merrill PT, Kim J, Cox TA, Betor CC, McCallum RM, Jaffe GJ. Uveitis in the southeastern United States. Curr Eye Res. 1997 Sep;16(9):865-74.
(1997)
Abstract
Jaffe GJ, Abrams GW, Williams GA, Han DP. Tissue plasminogen activator for postvitrectomy fibrin formation. Ophthalmology. 1990 Feb;97(2):184-9.
(1990)
Abstract
